NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
S5E3: What’s Next for Lipoprotein(a)? Insights from an Expert Discussion Group
Listen to Dr. Brown discuss with Dr. Koschinsky and Dr. Pena about how this important lipoprotein and potent cardiovascular risk marker is transitioning from the…
The ABCs of Lipoprotein(a)
In recent years, lipoprotein(a) [Lp(a)] has been recognized as a prevalent risk factor for cardiovascular disease. It is estimated that ~20% of the global population…
The Use of Colchicine for Secondary Cardiovascular Disease Prevention: What’s Old is New Again
Colchicine is an oral anti-inflammatory medication that interferes with neutrophil function and activation of IL-1β. The United States Food and Drug Administration-approved indications for colchicine…
Lipid Metabolism and Cardiovascular Disease in Patients with Renal Disease
Reduced estimated glomerular filtration rate (GFR) and chronic kidney disease (CKD) are also independently associated with the risk of death and cardiovascular (CV) events in community.(3) When compared to the general population, patients with CKD…
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Current Understanding of the Contribution of Lipoprotein(a) to Atherosclerotic Cardiovascular Disease Risk in Women
It is well-established that, compared to men, post-menopausal women enjoy a degree of protection against atherosclerotic cardiovascular disease (ASCVD).1 The rate of ASCVD in post-menopausal…
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice